Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02913105
Registration number
NCT02913105
Ethics application status
Date submitted
13/09/2016
Date registered
23/09/2016
Date last updated
5/01/2021
Titles & IDs
Public title
Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
Query!
Scientific title
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
Query!
Secondary ID [1]
0
0
CLMB763X2201
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-alcoholic Steatohepatitis NASH
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Diet and Nutrition
0
0
0
0
Query!
Obesity
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - LMB763
Treatment: Drugs - Placebo
Experimental: LMB763 - Oral dose once daily for 12 weeks (84 days)
Placebo Comparator: Placebo - Oral dose once daily for 12 weeks (84 days)
Treatment: Drugs: LMB763
Hard Gelatin Capsules
Treatment: Drugs: Placebo
Hard Gelatin Capsule
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. No statistical analysis was planned for this primary outcome measure.
Query!
Timepoint [1]
0
0
From date of First Participant First Treatment until Last Patient Last Visit (up to Day 112 (End of Study (EOS))
Query!
Primary outcome [2]
0
0
Change From Baseline in Alanine Aminotransferase (ALT) Levels
Query!
Assessment method [2]
0
0
ALT level assessment is one of the diagnostic parameters in Liver function test (LFT). Baseline was defined as the mean of ALT levels at baseline and pre-dose visits. Geometric Mean and Geometric Coefficient of Variation for change are based on log-transformed ratio to baseline (i.e., change from baseline in the log domain).
Query!
Timepoint [2]
0
0
Baseline to Day 84 (Week 12)
Query!
Secondary outcome [1]
0
0
Observed Maximum Plasma Concentration (Cmax) of LMB763
Query!
Assessment method [1]
0
0
No statistical analysis was planned for this outcome measure.
Query!
Timepoint [1]
0
0
0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Days 1 and 42
Query!
Secondary outcome [2]
0
0
Time to Reach Maximum Concentration (Tmax) of LMB763
Query!
Assessment method [2]
0
0
No statistical analysis was planned for this outcome measure.
Query!
Timepoint [2]
0
0
0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Days 1 and 42
Query!
Secondary outcome [3]
0
0
Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) of LMB763
Query!
Assessment method [3]
0
0
No statistical analysis was planned for this outcome measure.
Query!
Timepoint [3]
0
0
0 to 96 hours post-dose on Days 1 and 42
Query!
Secondary outcome [4]
0
0
Accumulation Ratio (Racc) of LMB763
Query!
Assessment method [4]
0
0
The drug accumulation ratio (Racc) is the ratio of accumulation of drug going from a single dose to steady state with repeated administration.
No statistical analysis was planned for this outcome measure.
Query!
Timepoint [4]
0
0
Day 42
Query!
Secondary outcome [5]
0
0
Change From Baseline in Percentage of Liver Fat as Measured by Magnetic Resonance Imaging (MRI)
Query!
Assessment method [5]
0
0
Participants were to undergo MRI twice (Baseline and End of Treatment) during the course of the study to quantitate liver fat. Baseline was defined as the last available measurement prior to the first dose. Geometric Mean and Geometric Coefficient of Variation for change are based on log-transformed ratio to baseline (i.e., change from baseline in the log domain).
Query!
Timepoint [5]
0
0
Baseline to Day 84 (Week 12)
Query!
Secondary outcome [6]
0
0
Change From Baseline in Weight
Query!
Assessment method [6]
0
0
Baseline was defined as the last available measurement prior to the first dose.
Query!
Timepoint [6]
0
0
Baseline to Days 28, 42, 56, 84 and 112 (EOS)
Query!
Secondary outcome [7]
0
0
Change From Baseline in Body Mass Index (BMI)
Query!
Assessment method [7]
0
0
Baseline was defined as the last available measurement prior to the first dose at specified visit (day).
Query!
Timepoint [7]
0
0
Baseline to Days 28, 42, 56, 84 and 112 (EOS)
Query!
Secondary outcome [8]
0
0
Change From Baseline in Waist to Hip Ratio
Query!
Assessment method [8]
0
0
Baseline was defined as the last available measurement prior to the first dose.
Query!
Timepoint [8]
0
0
Baseline to Days 28, 42, 56, 84 and 112 (EOS)
Query!
Secondary outcome [9]
0
0
Change From to Baseline in Liver Stiffness
Query!
Assessment method [9]
0
0
Fibroscan® was performed where available to assess liver stiffness. Baseline was defined as the last available measurement prior to the first dose. Geometric Mean and Geometric Coefficient of Variation for change are based on log-transformed ratio to baseline (i.e., change from baseline in the log domain).
Query!
Timepoint [9]
0
0
Baseline to Day 84 (Week 12)
Query!
Secondary outcome [10]
0
0
Change From Baseline in Enhanced Liver Fibrosis (ELF) Test Panel
Query!
Assessment method [10]
0
0
The ADVIA CentaurR systems' ELF™ test is an in vitro diagnostic multivariate index assay that provides a single score by combining quantitative measurements of hyaluronic acid (HA), amino-terminal propeptide of type III procollagen (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1) in human serum using the ADVIA Centaur XP, ADVIA Centaur XPT, and ADVIA Centaur CP systems in an algorithm. ELF score for the ADVIA Centaur systems is calculated by, first obtaining results for the ADVIA Centaur HA, PIIINP, and TIMP-1 assays and then using the following equation/algorithm:
ADVIA Centaur XP/XPT:
ELF score = 2.278 + 0.851 ln(CHA) + 0.751 ln(CP3NP) + 0.394 ln(CTIMP1)
ADVIA Centaur CP:
ELF score = 2.494 + 0.846 ln(CHA) + 0.735 ln(CP3NP) + 0.391 ln(CTIMP1) Concentrations (C) of each assay are in ng/mL
Interpretation of ELF score is as follows:
< 7.7 None to mild
7.7 to < 9.8 Moderate
9.8 Severe
Query!
Timepoint [10]
0
0
Baseline to Days 42 and 84
Query!
Secondary outcome [11]
0
0
Change From Baseline in Fibrosis Biomarker Test
Query!
Assessment method [11]
0
0
Fibrosis Biomarker test included hyaluronic acid (HA), amino-terminal pro-peptide of procollagen type III (PIIINP), and tissue inhibitor of metalloproteinases (TIMP-1) as markers of liver fibrosis. Baseline was defined as the last available measurement prior to the first dose. Geometric Mean and Geometric Coefficient of Variation for change are based on log-transformed ratio to baseline (i.e., change from baseline in the log domain).
Query!
Timepoint [11]
0
0
Baseline to Days 42 and 84
Query!
Secondary outcome [12]
0
0
Change From Baseline in Fasting Lipid Profile: Cholesterol (Chol) and Triglycerides (TG)
Query!
Assessment method [12]
0
0
Lipid measurements were collected under fasted conditions. Baseline was defined as the last available measurement prior to the first dose. Geometric Mean and Geometric Coefficient of Variation for change are based on log-transformed ratio to baseline (i.e., change from baseline in the log domain).
Query!
Timepoint [12]
0
0
Baseline to Days 7, 14, 28, 42, 56, 84 and 112 (EOS)
Query!
Secondary outcome [13]
0
0
Change From Baseline in Fasting Lipid Profile: High-density Lipoprotein (HDL) and Low-density Lipoprotein (LDL) Cholesterol
Query!
Assessment method [13]
0
0
Baseline was defined as the last available measurement prior to the first dose. Geometric Mean and Geometric Coefficient of Variation for change are based on log-transformed ratio to baseline (i.e., change from baseline in the log domain).
Query!
Timepoint [13]
0
0
Baseline to Days 7, 14, 28, 42, 56, 84 and 112 (EOS)
Query!
Secondary outcome [14]
0
0
Change From Baseline in Visual Analog Scale (VAS) for Itching of Skin
Query!
Assessment method [14]
0
0
A 10 cm VAS was used to assess the severity of participants itch (ranging from 0 = no itch at all to 10 = the worst imaginable itch). The score (distance from left) on the VAS was recorded by the participant marking with a line and used to test for an effect of LMB763 over placebo. Baseline was defined as the last available measurement prior to the first dose. A positive change from Baseline indicates improvement.
Query!
Timepoint [14]
0
0
Baseline to Day 84 (Week 12)
Query!
Eligibility
Key inclusion criteria
- Male/female patients, 18 years or older
- Written informed consent
- Presence of NASH by histologic evidence (liver biopsy) and elevated alanine
aminotransferase (ALT), OR phenotypic diagnosis of NASH based on elevated ALT, BMI and
diagnosis of Type 2 diabetes mellitus
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Current use of obeticholic acid (OCA)
- New initiation GLP-1 agonists such as liraglutide, exenatide , lixisenatide,
albiglutide or dulaglutide within 3 months of screening
- Pregnant or nursing (lactating) women
- Women of child-bearing potential, unless they are using highly effective methods of
contraception during dosing and for 5 days after stopping study medication
- Current or history of significant alcohol consumption for a period of more than 3
consecutive months within 1 year prior to screening
- Clinical evidence of hepatic decompensation or severe liver impairment
- Previous diagnosis of other forms of chronic liver disease
- Uncontrolled diabetes mellitus
- History or current diagnosis of ECG abnormalities
- Patients with contraindications to MRI imaging
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/10/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/09/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
122
Query!
Recruitment in Australia
Recruitment state(s)
NSW,WA
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - New Lambton
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2305 - New Lambton
Query!
Recruitment postcode(s) [2]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Hawaii
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Louisiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
North Carolina
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Tennessee
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Texas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Virginia
Query!
Country [10]
0
0
Georgia
Query!
State/province [10]
0
0
Tbilisi
Query!
Country [11]
0
0
Jordan
Query!
State/province [11]
0
0
Amman
Query!
Country [12]
0
0
New Zealand
Query!
State/province [12]
0
0
Auckland
Query!
Country [13]
0
0
New Zealand
Query!
State/province [13]
0
0
Christchurch
Query!
Country [14]
0
0
New Zealand
Query!
State/province [14]
0
0
Tauranga
Query!
Country [15]
0
0
New Zealand
Query!
State/province [15]
0
0
Wellington
Query!
Country [16]
0
0
Puerto Rico
Query!
State/province [16]
0
0
San Juan
Query!
Country [17]
0
0
Switzerland
Query!
State/province [17]
0
0
Bern
Query!
Country [18]
0
0
Switzerland
Query!
State/province [18]
0
0
Geneve 14
Query!
Country [19]
0
0
Switzerland
Query!
State/province [19]
0
0
Lugano
Query!
Country [20]
0
0
United Kingdom
Query!
State/province [20]
0
0
Devon
Query!
Country [21]
0
0
United Kingdom
Query!
State/province [21]
0
0
Glasgow
Query!
Country [22]
0
0
United Kingdom
Query!
State/province [22]
0
0
Portsmouth
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the present study is to assess the effects of LMB763 with respect to safety,
tolerability, and on markers of liver inflammation in patients with NASH
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02913105
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02913105
Download to PDF